Journal of International Oncology››2016,Vol. 43››Issue (10): 765-768.doi:10.3760/cma.j.issn.1673-422X.2016.10.010
Previous ArticlesNext Articles
Zhai Junshan, Li Nan
Online:
2016-10-08Published:
2016-09-07Contact:
Li Nan E-mail:xhk309@126.comSupported by:
National Nature Science Foundation of China (81101852)
Zhai Junshan, Li Nan. Anticancer effect and mechanism of miR-139[J]. Journal of International Oncology, 2016, 43(10): 765-768.
[1] Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions[J]. Brief Bioinform, 2014, 15(1): 1-19. DOI: 10.1093/bib/bbs075. [2] Sun C, Sang M, Li S, et al. HsamiR1395p inhibits proliferation and causes apoptosis associated with downregulation of cMet[J]. Oncotarget, 2015, 6(37): 39756-39792. DOI: 10.18632/oncotarget.5476. [3] Radfar MH, Wong W, Morris Q. Computational prediction of intronic microRNA targets using host gene expression reveals novel regulatory mechanisms[J]. PLoS One, 2011, 6(6): e19312. DOI: 10.1371/journal.pone.0019312. [4] Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters[J]. Genes Dev, 2008, 22(22): 3172-3183. DOI: 10.1101/gad.1706508. [5] Shen K, Mao R, Ma L, et al. Posttranscriptional regulation of the tumor suppressor miR1395p and a network of miR1395pmediated mRNA interactions in colorectal cancer[J]. FEBS J, 2014, 281(16): 3609-3624. DOI: 10.1111/febs.12880. [6] Bao W, Fu HJ, Xie QS, et al. HER2 interacts with CD44 to upregulate CXCR4 via epigenetic silencing of microRNA139 in gastric cancer cells[J]. Gastroenterology, 2011, 141(6): 2076-2087.e6. DOI: 10.1053/j.gastro.2011.08.050. [7] Watanabe K, Amano Y, Ishikawa R, et al. Histone methylationmediated silencing of miR139 enhances invasion of nonsmallcell lung cancer[J]. Cancer Med, 2015, 4(10): 1573-1582. DOI: 10.1002/cam4.505. [8] Zhang L, Dong Y, Zhu N, et al. microRNA1395p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer[J]. Mol Cancer, 2014, 13: 124. DOI: 10.1186/1476459813124. [9] Guo H, Hu X, Ge S, et al. Regulation of RAP1B by miR139 suppresses human colorectal carcinoma cell proliferation[J]. Int J Biochem Cell Biol, 2012, 44(9): 1465-1472. DOI: 10.1016/j.biocel.2012.05.015. [10] Shen K, Liang Q, Xu K, et al. MiR139 inhibits invasion and metastasis of colorectal cancer by targeting the type Ⅰ insulinlike growth factor receptor[J]. Biochem Pharmacol, 2012, 84(3): 320-330. DOI: 10.1016/j.bcp.2012.04.017. [11] Song M, Yin Y, Zhang J, et al. MiR1395p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1[J]. Protein Cell, 2014, 5(11): 851-861. DOI: 10.1007/s1323801400935. [12] Wong CC, Wong CM, Tung EK, et al. The microRNA miR139 suppresses metastasis and progression of hepatocellular carcinoma by downregulating Rhokinase 2[J]. Gastroenterology, 2011, 140(1): 322-331. DOI: 10.1053/j.gastro.2010.10.006. [13] Fan Q, He M, Deng X, et al. Derepression of cFos caused by microRNA139 downregulation contributes to the metastasis of human hepatocellular carcinoma[J]. Cell Biochem Funct, 2013, 31(4): 319-324. DOI: 10.1002/cbf.2902. [14] Gu W, Li X, Wang J. miR139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF4 pathway[J]. Oncol Rep, 2014, 31(1): 397-404. DOI: 10.3892/or.2013.2831. [15] Qiu G, Lin Y, Zhang H, et al. miR1395p inhibits epithelialmesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2[J]. Biochem Biophys Res Commun, 2015, 463(3): 315-321. DOI: 10.1016/j.bbrc.2015.05.062. [16] Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus nontumorous tissues[J]. J Gastroenterol Hepatol, 2009, 24(4): 652-657. DOI: 10.1111/j.14401746.2008.05666.x. [17] Kang HS, Kim J, Jang SG, et al. MicroRNA signature for HER2positive breast and gastric cancer[J]. Anticancer Res, 2014, 34(7): 3807-3810. . [18] Zhang Y, Shen WL, Shi ML, et al. Involvement of aberrant miR139/Jun feedback loop in human gastric cancer[J]. Biochim Biophys Acta, 2015, 1853(2): 481-488. DOI: DOI: 10.1016/j.bbamcr.2014.12.002. [19] Krishnan K, Steptoe AL, Martin HC, et al. miR1395p is a regulator of metastatic pathways in breast cancer[J]. RNA, 2013, 19(12): 1767-1780. DOI: 10.1261/rna.042143.113. [20] Rask L, Balslev E, Skilde R, et al. Differential expression of miR139, miR486 and miR21 in breast cancer patients subclassified according to lymph node status[J]. Cell Oncol (Dordr), 2014, 37(3): 215-227. DOI: 10.1007/s1340201401766. [21] Hua W, Sa KD, Zhang X, et al. MicroRNA139 suppresses proliferation in luminal type breast cancer cells by targeting topoisomerase Ⅱ alpha[J]. Biochem Biophys Res Commun, 2015, 463(4): 1077-1083. DOI: 10.1016/j.bbrc.2015.06.061. [22] Zhang HD, Sun DW, Mao L, et al. MiR1395p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel[J]. Biochem Biophys Res Commun, 2015, 465(4): 702-713. DOI: 10.1016/j.bbrc.2015.08.053. [23] Luo HN, Wang ZH, Sheng Y, et al. MiR139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells[J]. Med Oncol, 2014, 31(1): 789. DOI: 10.1007/s120320130789z. [24] Liu R, Yang M, Meng Y, et al. Tumorsuppressive function of miR1395p in esophageal squamous cell carcinoma[J]. PLoS One, 2013, 8(10): e77068. DOI: 10.1371/journal.pone.0077068. [25] Dai S, Wang X, Li X, et al. MicroRNA1395p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme[J]. Biochem Biophys Res Commun, 2015, 467(2): 204-210. DOI: 10.1016/j.bbrc.2015.10.006. [26] Emmrich S, Engeland F, ElKhatib M, et al. miR1395p controls translation in myeloid leukemia through EIF4G2[J]. Oncogene, 2016, 35(14): 1822-1831. DOI: 10.1038/onc.2015.247. [27] Zhang HD, Jiang LH, Sun DW, et al. MiR1395p: promising biomarker for cancer[J]. Tumour Biol, 2015, 36(3): 1355-1365. DOI: 10.1007/s1327701531993. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||